 |
PDBsum entry 5eud
|
|
|
|
References listed in PDB file
|
 |
|
Key reference
|
 |
|
Title
|
 |
Creation of a s1p lyase bacterial surrogate for structure-Based drug design.
|
 |
|
Authors
|
 |
M.A.Argiriadi,
D.Banach,
E.Radziejewska,
S.Marchie,
J.Dimauro,
J.Dinges,
E.Dominguez,
C.Hutchins,
R.A.Judge,
K.Queeney,
G.Wallace,
C.M.Harris.
|
 |
|
Ref.
|
 |
Bioorg Med Chem Lett, 2016,
26,
2293-2296.
[DOI no: ]
|
 |
|
PubMed id
|
 |
|
 |
|
|
 |
 |
|
Abstract
|
 |
|
S1P Lyase (SPL) has been described as a drug target in the treatment of
autoimmune diseases. It plays an important role in maintaining intracellular
levels of S1P thereby affecting T cell egress from lymphoid tissues. Several
groups have already published approaches to inhibit S1P Lyase with small
molecules, which in turn increase endogenous S1P concentrations resulting in
immunosuppression. The use of structural biology has previously aided SPL
inhibitor design. Novel construct design is at times necessary to provide a
reagent for protein crystallography. Here we present a chimeric bacterial
protein scaffold used for protein X-ray structures in the presence of early
small molecule inhibitors. Mutations were introduced to the bacterial SPL from
Symbiobacterium thermophilum which mimic the human enzyme. As a result, two
mutant StSPL crystal structures resolved to 2.8Å and 2.2Å resolutions were
solved and provide initial structural hypotheses for an isoxazole chemical
series, whose optimization is discussed in the accompanying paper.
|
 |
|
|
|
|
 |